Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges

S Zeng, W Huang, X Zheng, Z Zhang, J Wang… - European journal of …, 2021 - Elsevier
Proteolysis targeting chimera (PROTAC), hijacking protein of interest (POI) and recruiting E3
ligase for target degradation via the ubiquitin-proteasome pathway, is a novel drug …
被引用次数：133 相关文章

[引用][C] Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges

S Zeng, W Huang, X Zheng - European Journal of Medicinal Chemistry, 2021 - cir.nii.ac.jp
Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and
future challenges | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ …

Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges

S Zeng, W Huang, X Zheng, L Cheng… - European journal …, 2021 - pubmed.ncbi.nlm.nih.gov
Proteolysis targeting chimera (PROTAC), hijacking protein of interest (POI) and recruiting E3
ligase for target degradation via the ubiquitin-proteasome pathway, is a novel drug …

Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges.

S Zeng, W Huang, X Zheng, L Cheng… - European Journal of …, 2020 - europepmc.org
Proteolysis targeting chimera (PROTAC), hijacking protein of interest (POI) and recruiting E3
ligase for target degradation via the ubiquitin-proteasome pathway, is a novel drug …